Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
3-hydroxy-3-methylglutaric aciduria (3HMG) is an organic aciduria, due to deficiency of 3-hydroxy-3-methylglutaryl-CoA-lyase (a key enzyme in ketogenesis and leucine metabolism) usually presenting in infancy with episodes of metabolic decompensation triggered by periods of fasting or infections, which when left untreated are life-threatening and may lead to neurological sequelae.
Data assembled from 8 of 12 sources · Last updated Oct 3, 2026, 10:32 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Features include always present findings: Reduced HMG-CoA lyase activity in cultured fibroblasts and Metabolic acidosis; and very common findings: Elevated serum anion gap, Hyperammonemia, Hypoglycemia, and Nonketotic hypoglycemia. 70 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 17 | Encephalopathy, Seizure, Hyporeflexia |
Digestive system | 8 | Enlarged liver (hepatomegaly), Diarrhea, Episodic vomiting |
Lab test results | 5 | Elevated serum anion gap, Elevated circulating alanine aminotransferase concentration, Elevated circulating aspartate aminotransferase concentration |
Blood and immune system | 4 | Low red blood cell count (anemia), Low white blood cell count (decreased total leukocyte count), Elevated platelet count (thrombocytosis) |
Heart and blood vessels | 2 | Cardiac arrest, Enlarged and weakened heart (dilated cardiomyopathy) |
Metabolism | 2 | Fever, Metabolic acidosis |
Muscles | 1 | Low muscle tone (hypotonia) |
Kidneys and urinary system | 1 | Elevated urinary 3-methylcrotonylglycine level |
Head and neck | 1 | Microcephaly |
Growth and development | 1 | Weight loss |
Lungs and breathing | 1 | Apnea |
HMGCL encodes 3-hydroxy-3-methylglutaryl-CoA lyase (325 aa). Mitochondrial 3-hydroxy-3-methylglutaryl-CoA lyase that catalyzes a cation-dependent cleavage of (S)-3-hydroxy-3-methylglutaryl-CoA into acetyl-CoA and acetoacetate, a key step in ketogenesis. Highest expression in Liver (77.6 TPM) and Adrenal Gland (34.4 TPM).
3-hydroxy-3-methylglutaric aciduria is caused by mutations in the HMGCL gene on chromosome 1.
The HMGCL protein participates in HMG CoA = acetoacetic acid + acetyl CoA pathway.
HMGCL is classified as a druggable target (Enzyme category) with score 0.0.
Genetic testing for HMGCL is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for 3-hydroxy-3-methylglutaric aciduria has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 4 very common features, 19 common features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
14 publications have been identified in PubMed for 3-hydroxy-3-methylglutaric aciduria. Research spans Case Report / Case Series (57%), Review / Meta-Analysis (21%), and Diagnostic / Biomarker (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 57% |
Research summaries | 3 | 21% |
Testing and diagnosis research | 1 | 7% |
Laboratory research | 1 | 7% |
Disease patterns and progression | 1 | 7% |
Yang C (2026). [PMID: 41625680](https://pubmed.ncbi.nlm.nih.gov/41625680/). *O G Open*. [Case Report / Case Series]
Newman S (2026). [PMID: 41529426](https://pubmed.ncbi.nlm.nih.gov/41529426/). *Mol Genet Metab*. [Review / Meta-Analysis]
Yang K (2026). [PMID: 41872807](https://pubmed.ncbi.nlm.nih.gov/41872807/). *BMC Pediatr*. [Case Report / Case Series]
Bjelica M (2025). [PMID: 40513556](https://pubmed.ncbi.nlm.nih.gov/40513556/). *J Pediatr Endocrinol Metab*. [Case Report / Case Series]
Jennings EA (2025). [PMID: 40252717](https://pubmed.ncbi.nlm.nih.gov/40252717/). *Clin Chim Acta*. [Review / Meta-Analysis]
Nyktari V (2025). [PMID: 41156202](https://pubmed.ncbi.nlm.nih.gov/41156202/). *J Clin Med*. [Case Report / Case Series]
Menkovic I (2025). [PMID: 41323099](https://pubmed.ncbi.nlm.nih.gov/41323099/). *Mol Genet Metab Rep*. [Case Report / Case Series]
Kılıç M (2025). [PMID: 41636194](https://pubmed.ncbi.nlm.nih.gov/41636194/). *Turk J Pediatr*. [Case Report / Case Series]
Aukes R (2025). [PMID: 40937535](https://pubmed.ncbi.nlm.nih.gov/40937535/). *J Inherit Metab Dis*. [Review / Meta-Analysis]
Demetriadou A (2025). [PMID: 40255048](https://pubmed.ncbi.nlm.nih.gov/40255048/). *J Inherit Metab Dis*. [Case Report / Case Series]
AI-curated news mentioning 3-hydroxy-3-methylglutaric aciduria
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.